About DMC Biotechnologies
DMC Biotechnologies is a company based in Boulder (United States) founded in 2014 by Mike Lynch and Matt Lipscomb. It operates as a Product-as-a-Service, and Direct-to-Consumer (D2C). DMC Biotechnologies has raised $55.04 million across 14 funding rounds from investors including Michelin, SCG and Toyobo Global. DMC Biotechnologies offers products and services including D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals. DMC Biotechnologies operates in a competitive market with competitors including LanzaTech, Evonik, Again, Manus Bio and Proklean Technologies, among others.
- Headquarter Boulder, United States
- Founders Mike Lynch, Matt Lipscomb
-
Sectors
Chemicals & Materials
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dmc Biotechnologies, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$55.04 M (USD)
in 14 rounds
-
Latest Funding Round
$1.41 M (USD), Series C
Dec 16, 2025
-
Investors
Michelin
& 16 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DMC Biotechnologies
DMC Biotechnologies offers a comprehensive portfolio of products and services, including D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A sustainable nutraceutical ingredient for modern formulation needs.
A cleaner, fermented ingredient for health-focused brand formulations.
Sustainable chemicals produced for diverse industrial market applications.
Unlock access to complete
Funding Insights of DMC Biotechnologies
DMC Biotechnologies has successfully raised a total of $55.04M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $1.41 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Series C — $1.4M
-
First Round
First Round
(01 Jan 2016)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Series C - DMC Biotechnologies | Valuation |
investors |
|
| Oct, 2025 | Amount | Series C - DMC Biotechnologies | Valuation |
investors |
|
| Apr, 2025 | Amount | Series C - DMC Biotechnologies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DMC Biotechnologies
DMC Biotechnologies has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Michelin, SCG and Toyobo Global. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Growth-stage life sciences and tech companies in Europe are funded.
|
Founded Year | Domain | Location | |
|
Investment funds focused on sustainable food and agriculture are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DMC Biotechnologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - DMC Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dmc Biotechnologies Comparisons
Competitors of DMC Biotechnologies
DMC Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LanzaTech, Evonik, Again, Manus Bio and Proklean Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Waste carbon is treated via a bio-processing platform.
|
|
| domain | founded_year | HQ Location |
Green specialty chemicals are developed and supplied for multiple industries.
|
|
| domain | founded_year | HQ Location |
Chemicals and fertilizers are produced from industrial CO2 waste.
|
|
| domain | founded_year | HQ Location |
Phytochemicals are developed using microbial fermentation processes.
|
|
| domain | founded_year | HQ Location |
Probiotic-based cleaning agents are manufactured for industrial use.
|
|
| domain | founded_year | HQ Location |
Green chemicals are developed using microcapsule technology for sustainability.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dmc Biotechnologies
Frequently Asked Questions about DMC Biotechnologies
When was DMC Biotechnologies founded?
DMC Biotechnologies was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is DMC Biotechnologies located?
DMC Biotechnologies is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Who is the current CEO of DMC Biotechnologies?
Jim Flatt is the current CEO of DMC Biotechnologies.
Is DMC Biotechnologies a funded company?
DMC Biotechnologies is a funded company, having raised a total of $55.04M across 14 funding rounds to date. The company's 1st funding round was a Series C of $4.79M, raised on Jan 01, 2016.
What does DMC Biotechnologies do?
DMC Biotechnologies is focused on transforming the specialty chemical industry by producing sustainable, bio-based ingredients using precision fermentation. Operations span dietary supplements, nutraceuticals, cosmetic actives, and bio-based chemicals for various markets. The proprietary Dynamic Metabolic Control technology is utilized to ensure cost-effective, reliable, and scalable production. Emphasis is placed on environmental responsibility, safety, and health standards. Collaborations are fostered to accelerate product development from concept to commercial scale, while supply chain security is enhanced through local production using agricultural feedstocks.
Who are the top competitors of DMC Biotechnologies?
DMC Biotechnologies's top competitors include Manus Bio, LanzaTech and Mint Innovation.
What products or services does DMC Biotechnologies offer?
DMC Biotechnologies offers D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals.
Who are DMC Biotechnologies's investors?
DMC Biotechnologies has 17 investors. Key investors include Michelin, SCG, Toyobo Global, Solvay, and Capricorn Partners.